The effects of hydrallazine and hexamethonium salts on blood pressure and related functions have been studied in a series of ambulatory and hospitalized hypertensive patients as well as in experimentally induced hypertension (rats and dogs). Comparative observations have also been made on the effects of tetraethylammonium chloride and Dibenzyline, a congener of dibenzylchlorethylamine (Dibenamine). Critical evaluation of the data indicates that the effectiveness of hydrallazine and hexamethonium salts, when used either alone or in combination, is not significantly greater in long term administration than that of previously existing regimens in the treatment of hypertensive vascular disease.
T HE TREATMENT of hypertension by specific drug therapy has received renewed impetus with the introduction of potent sympatholytic agents. These have been advocated as a means of lowering the arterial blood pressure for prolonged periods of time, with consequent amelioration of the hypertensive vascular disease.'-' However, the level of the blood pressure in hypertensive patients varies considerably during the natural history of the disease and is influenced by a variety of nonspecific factors,5-9 including changes in the psychodynamics of the individual's personality and the impact of the doctor-patient relationship.9 10 Moreover, the level of blood pressure, per se, is often an inadequate guide to the severity and progression of the vascular complications.7' 8 These considerations emphasize the difficulty in establishing the ultimate value of hypotensive agents. Because of their widespread use and potential dangers," a critical study of their effects was undertaken which incorporated certain principles minimizing the aforementioned difficulties.
METHODS AND MATERIALS
Three groups of patients were studied: (1) 10 hypertension from the Hypertension Clinic of Parkland Hospital who were treated with hydrallazine chloride (Apresoline); (2) 12 hospitalized patients with hypertensive disease of varying severity treated with hexamethonium bromide and/or hydrallazine chloride; (3) 13 hospitalized hypertensive patients given intravenous injections of the drugs under study to evaluate their immediate effects. The clinical findings for the patients in each of the three groups are summarized in tables 1 through 3 respectively.
The 10 outpatients were seen by one investigator who determined all the blood pressures. Hydrallazine and a placebo were alternated in such a manner as to b3 entirely unknown to either patient or investigator. The daily dose was divided into three or four portions per day and office visits, at one or two-week intervals, were scheduled two or three hours after the last dose. An average of five blood pressure determinations at one-minute intervals, with the patient reclining, and an average of two determinations, with the patient standing, were recorded at each visit. Because of the nature of the study, the patients received considerably more attention by the physician than they had in their previous routine clinic visits. One patient died during the study and one discontinued therapy; the remaining eight were on drug or placebo for a total of 13 to 32 weeks.
In the hospitalized patients, drug-placebo alternation was known to the investigator, but not to the trained ward personnel who determined the blood pressures. Moreover, in the early phase of the study, even the fact that such alternation was contemplated was unknown to these individuals. Hexamethonium bromide and hydrallazine chloride in combination was given to eight patients, hydralCirculation, Volume VIII, August, 1953 188 lazine alone to three, and hexamethonium alone to one. Hydrallazine* was administered orally at 6 a.m., 12:00 Noon, and 6:00 p.m.; hexamethonium* intramuscularly at 9:00 a.m. and 9:00 p.m., with a 3:00 p.m. dose added later in most patients. One patient received both medications simultaneously at four hour intervals from 6:00 a.m. to 10:00 p.m. Each medication was started separately and carried either to the point of maximum effect or to the development of side-effects before the other was added. Further increments to one or both were then given if apparent diminution of the hypotensive action of the drugs developed. Placebos were substituted in a random manner, before, during, or after specific therapy. The blood pressures were recorded at regular intervals, with the patient reclining, from three to eight times per day and a daily average then determined. It has been our experience that variations in the "resting blood pressure"1 from day to day are no less than those seen spontaneously during any given day; consequently, the daily average represents a reliable estimation of the day to day variation.
In the studies of acute effects, hydrallazine chloride, hexamethonium bromide and/or tetraethylammonium chloride (TEAC) and in three patients Dibenzyline (SKF 688A), were administered on consecutive days, in the order indicated in table 3 . Five readings at one-minute intervals were determined with the patient reclining. The drug was then administered intravenously by direct injection, except on two occasions when Dibenzyline was administered as a constant infusion. AIeasurements of blood pressure were continued at one-half to one-minute intervals until the peak action of the drug had passed and the blood pressure had stabilized. The percentage fall in diastolic pressure was calculated from the lowest point reached by the diastolic blood pressure and the average of the five initial determinations. Usually the systolic blood pressure was also at its lowest at this time.
The studies on experimental hypertension were carried out on rats and dogs rendered hypertensive by the application of a figure-of-eight ligature to one kidney with removal of the contralateral organ. '8 The experimental procedures were identical to those used in previous studies in this laboratory,.14 15 The blood pressures were determined on trained unanesthetized animals by the method of Kersten and co-workers"6 in the rats, and by puncture of the femoral aitery and direct reading on a mercury manometer in the dogs.'7 In the rats, the drugs were administered by intraperitoneal injection or orally by admixture with the animals' food; in the dogs, the drugs were injected intravenously or intramuscularly or fed by enclosing the medication within a bolus of meat. figure 1 . In none of the patients did the blood pressure decrease significantly during periods on the drug. The alternating periods of drug and placebo revealed that elevations and declines in blood pressure were essentially unrelated to which preparation was being administered. In only one patient (M. E., fig. 1 ) were the blood pressures consistently lower during drug therapy, but the difference, as indicated in table 1, when all placebo and drug periods are averaged, amounts to only 9/8 mm. Hg. Among the entire group, the largest systolic difference was 13 mm. Hg in patient E. L.; the largest diastolic difference was 8 mm. Hg in patient M. E.
Pulse rates were consistently higher during the periods on drug therapy, ranging from 1 to 19 per minute (average, 6.4). Significant postural hypotension was not noted.
The gradual fall of the blood pressure during the early weeks of the experiment and in several instances throughout the course of observation was quite striking (patients M. F. and D. H., fig. 1 ). Comparison of the blood pressures on first visits with those on the last week of therapy indicated that these overall declines were usually of greater magnitude than those attributable to the drug (table 1).
All patients improved symptomatically during the course of the study, irrespective of whether placebo or drug was being administered. They "felt better" and expressed a relief of headaches, weakness, and fatigue. Even patient R. S., who had a duodenal ulcer in addition to severe hypertension and who died with rapidly progressive renal failure following the development of pyloric stenosis, had reported improvement prior to this terminal event.
The drug produced side effects which limited further increase in dosage in 8 of the 10 7. E. C., with grade IV fundi but only moderate renal impairment, had a blood pressure of 228/150 mm. Hg on admission; within five days, the diastolic had fallen to a level of 98 mm. Hg while on a low sodium diet. The blood pressure then increased, despite continuation of the diet, to a diastolic level of 130 mm. Hg. With the administration of hexamethonium, the diastolic level ranged from 100 to 120 mm. Hg but this was not decreased further by the addition of hydrallazine, nor was it affected by a return to a regular diet. When the drugs were replaced by placebos after five weeks of combined therapy, the blood pressure rose slightly but remained below its initial levels and at the time of discharge had stabilized at 120 to 140 mm. Hg. Hexamethonium produced incapacitating postural hypotension in this patient, while headaches, which were present throughout his hospital stay, were aggravated by hydrallazine. Initially, intravenous test doses of hydrallazine (C-5968) produced a marked although transient fall in blood pressure with relief of severe headache. When continued, intravenous hydrallazine induced severe headaches and had to be discontinued; nevertheless, blood pressure did not return to the high levels recorded on admission. When hexamethonium (C-6) and hydrallazine in combination were administered, the blood pressure declined temporarily, but severe headaches necessitated discontinuance of drug therapy, after which the blood pressure continued to rise. When the drugs were reinstituted, the blood pressure again declined; however, renal function deteriorated further as reflected in the rising blood urea nitrogen. After several days of absence from the hospital without therapy, during which time the blood urea nitrogen fell, therapy was reinstituted; the blood pressure declined, but renal failure progressed and the patient expired.
244/162 mm. Hg. Hexamethonium and hydrallazine were administered up to a dosage of 100 mg. and 450 mg. per day, respectively, with further increase precluded by the development of postural hypotension. Diastolic blood pressure declined to 136 mm. Hg but then gradually rose to 143 to 154 mm. despite continuation of the maximum tolerated dose.
were achieved early in the course, could not be maintained. A low sodium diet, instituted during several phases of his treatment, had no significant effect. Despite reinstitution of both drugs following discharge from the hospital, the blood pressure returned to its preadmission levels and progressive vascular damage developed. S. with grade IV fundi and severe renal impairment was in congestive heart failure on admission. The latter was controlled with digitoxin and mercurials with a decrease in blood pressure.
With hexamethonium and hydrallazine therapy, only a transient further decline occurred even when the dose was increased to 250 mg. and 1.0 Gm. per day, respectively, with both agents given simultaneously. Severe with grade II fundi and moderate renal impairment displayed a striking decline in blood pressure when given placebos while on a low sodium diet and while being treated for a urinary tract infection. The addition of hexamethonium and hydrallazine in doses up to 50 and 450 mg. per day, respectively, caused no additional fall. The blood pressure which was 240/140 mm. Hg on admission, had declined by the time of discharge to 164/102 mm., although all specific medications had been discontinued 10 days previously and she had been on a regular diet for over one month. The results with oral administration are summarized in figure 6. It will be noted that on continued administration of these large doses the decline in blood pressure was only moderate and was not sustained.
2. The Dog. Results comparable to those obtained in the rat were also noted when the drugs were injected or administered orally to the hypertensive dog. In general, however, the dog was more reactive and more pronounced decrements in blood pressure were obtained with comparable doses based on the relative surface areas of the two species. Nausea and vomiting, however, were common concomitants of therapy and were observed when the blood pressure declined 30 mm. Hg or more.
The intramuscular injection of tetraethylammonium chloride in doses of 20 mg That these agents have immediate hypotensive effects, especially when given parenterally, is undisputed. On the other hand, the maintenance of hypotensive effects, which others have reported [1] [2] [3] [4] and which were often noted in our patients, are not necessarily attributable to the action of drugs. Evaluation of long term administration must take into consideration other factors which w-ill impinge upon the patient and influence the blood pressure.9 Hospitalized hypertensive patients undergoing no specific treatment, for instance, regularly reveal a fall in blood pressure, even when malignant acceleration is present; precisely when such a decline will occur in relationship to the duration of hospitalization cannot be predicted. 19, 20 These effects of hospitalization are not simply a result of bed rest or relief from physical exertion; as a matter of fact, these patients whenever possible were encouraged to be ambulatory. Entrance into the hospital may constitute an escape from an emotionally stressful situation. A doctorpatient relationship which is reassuring and supportive may be developed; this is particularly true in an experimental study where special attention is given to the patient. These considerations apply equally to individuals treated on an outpatient status, especially when the administration of a new agent is associated with newt enthusiasms and positive and supportive attitudes on the part of the physicianl.9' 22 Conversely, stress, including that produced by disturbances in the doctor-patient relationship, may counteract the hypotensive effects of any therapeutic regimen.'21-'23 Such was apparent in patient J. B. whose family situation required his return to work, making hospitalization intolerable, and in patient MI. M. from whom metabolic studies demanded cooperation which taxed her capacity so that hospitalization became threatening. Objections to the rigid regimen of treatment similarly affected the course in other patients both in the outpatient and hospitalized groups.
Side effects occurred frequently and constituted serious deterrents to continued therapy. These included postural hypotension, blurring of vision, urinary retention, and constipation with hexamethonium and headache, nausea, and vomiting with hydrallazine. The significance of side effects, however, must also be cautiously evaluated, as evidenced by the appearance of typical "hydrallazinie headaches" in several instances during administration of placebos. Similarly, relief of symptoms which did not coincide with physical improvement was frequently noted.
Certain of the difficulties in evaluation imposed by the factors just discussed can be minimized by adequate control measures. The use of placebos, however, is of itself insufficient. As others have pointed out and as this study again emphasizes, their substitution should be unknown both to investigator as well as to subject.2 25 Moreover, parallel observations of the changing life situations and stresses acting on the patient are necessary, as are observations of the doctor-patient, or investigatorsubject, relationship, since this represents an 1.96 important factor in the patient's current life situation while under treatment.9
The results on experimentally induced hypertension in rats and dogs, in whom a more objective evaluation of the direct effect of drugs on the blood pressure can be obtained, are in accord with our results in patients. Significant declines resulted only with doses much larger than tolerated by man. Such declines were not sustained with continued administration while about a third of the animals died when the treatment was extended beyond three or four consecutive days.
Our 4 . In evaluating the clinical effects of hypotensive agents, the need was emphasized for assessing other factors which are known to influence blood pressure and which cannot be completely eliminated from any study. This pertained particularly to the effects of hospitalization and the doctor-patient relationship.
5. A more objective evaluation of hydrallazine, hexamethonium, tetraethylammonium chloride, and Dibenzyline chloride was possible in the rat and dog with experimental hypertension. Here the results in the unanesthetized animal indicated appreciable depressor effects only when used acutely and in dosages several times as great as are tolerated by the human. SUMARIo ESPAROL Los efectos de las sales de hydrallazine y hexamethonium en la presion arterial y funciones relacionadas han sido estudiados en una serie de pacientes hipertensos ambulatorios y aislados asi como tambien en hipertension inducida experimentalmente (perros y gatos). Observaciones comparativas tambi6n se han hecho sobre los efectos del cloruro de tetraetiloamonio y el Dibensyline, congenere del dibencilocloroetilamina (Dibenamine). Evaluacion critica de los datos indica que la efectividad de las sales de hydrallazine y hexamethonium, cuando son usadas aisladamente o en combinaci6n, no es significativamente mayor en el tratamiento por largo tiempo que el de los regimenes previamente existentes en el tratamiento de la enfermedad hipertenso vascular.
